These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Miller LS; Houchens D; Cheng R; Kaplan D; Goeckeler W Cancer Res; 1991 Jun; 51(11):2889-96. PubMed ID: 1851665 [TBL] [Abstract][Full Text] [Related]
10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]
11. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946 [TBL] [Abstract][Full Text] [Related]
12. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors. Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330 [TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505 [TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168 [TBL] [Abstract][Full Text] [Related]
16. Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts. Roberson PL; Yokoyama S; Rogers BE; Buchsbaum DJ Cancer Biother Radiopharm; 2003 Apr; 18(2):239-47. PubMed ID: 12804050 [TBL] [Abstract][Full Text] [Related]
17. A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study. Satterlee AB; Attayek P; Midkiff B; Huang L Radiat Oncol; 2017 Mar; 12(1):54. PubMed ID: 28302144 [TBL] [Abstract][Full Text] [Related]
18. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543 [TBL] [Abstract][Full Text] [Related]
19. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605 [TBL] [Abstract][Full Text] [Related]
20. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]